Top

Published in:

01-01-2013 | SCLERODERMA (J VARGA, SECTION EDITOR)

Management of Raynaud’s Phenomenon and Digital Ischemia

Author: Ariane L. Herrick

Published in: Current Rheumatology Reports | Issue 1/2013

Abstract

This review focuses on new findings and developments relevant to the clinician caring for patients with primary and secondary [especially systemic sclerosis (SSc)-related] Raynaud phenomenon (RP). In the last 18 months, several clinical trials and observational studies of RP and of SSc-related digital ulceration have been published, reflecting increased awareness of disease burden and increased interest by pharmaceutical companies: new insights into pathophysiology are driving new approaches to treatment. Key developments are the increased use of phosphodiesterase type V inhibitors in severe RP, and of bosentan (an endothelin-1 receptor antagonist) for prevention of recurrent SSc-related digital ulcers. Other treatments being researched include topical glyceryl trinitrate (applied locally to the digits), botulinum toxin (for severe digital ischemia/ulceration), and several other drugs including oral prostanoids. Increased availability and interest in nailfold capillaroscopy, by facilitating early diagnosis of SSc, should pave the way for studies of early intervention and vascular protection.

Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud’s phenomenon in general practice. BMJ. 1990;301:590–2.PubMedCrossRef

Tiev KP, Diot E, Clerson P, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie). J Rheum. 2009;36:1470–6.PubMedCrossRef

Khimdas S, Harding S, Bonner A, et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group Registry. Arthritis Care Res. 2011;63:142–9.CrossRef

• Mouthon L, Mestre-Stanislas C, Berezne A, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis. 2010;69:214–7. This study of 213 patients with SSc highlighted the functional impact and disease burden of digital ulceration. The 67 (31.4 %) patients with digital ulcers, compared to those without, had higher global disability (as measured by the Health Assessment Questionnaire), increased hand disability (measured by the Cochin Hand Function Scale), and reduced hand and wrist mobility.PubMedCrossRef

LeRoy EC, Medsger TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485–8.PubMed

Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum. 2005;52:1259–63.PubMedCrossRef

Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620–8.PubMedCrossRef

• Stewart M, Morling JR. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database of Systematic Reviews 2012; Issue 7. Art. No.: CD006687. doi: 10.1002/14651858.CD006687.pub3. This Cochrane review of oral vasodilators (excluding calcium channel blockers) concluded that at present there is no evidence base to support the effectiveness of any of these drugs in PRP. The review therefore highlights the urgent need for well-designed clinical trials.

Huissstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud’s phenomenon: a systematic review. Arch Phys Med Rehabil. 2011;92:1166–80.CrossRef

10.

• Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatol. 2010;49:2420–8. This double-blind, placebo-controlled, cross-over trial of 6 weeks of alternate day tadalafil 20 mg in 24 patients (23 with SSc) reported benefit in a number of clinical parameters including RP symptoms (frequency and duration of attacks, and Raynaud’s Condition Score), digital ulceration, and quality of life measures.CrossRef

11.

• Herrick AL, Van den Hoogen F, Gabrielli A, et al. Modified-Release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63:775–82. This multicentre double-blind, placebo-controlled clinical trial in patients with limited cutaneous SSc provided further evidence in favour of phosphodiesterase inhibiton for secondary RP. Four weeks’ modified release sildenafil (100 mg for 3 days then 200 mg daily) led to a greater reduction in mean percentage change in the number of RP attacks per week than placebo (−44.0 vs. −18.1 %, P = 0.034). Other endpoints were not significantly different between groups.PubMedCrossRef

12.

• Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012;172:1182–4. This single-centre double-blind, placebo controlled cross-over trial in 53 patients (6 primary, 47 secondary) reported a significant reduction (by −0.45) in Raynaud’s Condition Score on vardenafil compared to placebo (P = 0.03). The number and duration of attacks also fell significantly more on vardenafil.PubMed

13.

Pope J, Harding S, Khimdas S, et al. Agreement with guidelines from a large database for management for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol. 2012;39:524–31.PubMedCrossRef

14.

Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails – a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42–55.PubMedCrossRef

15.

Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon. Arthritis Rheum. 2009;60:870–7.PubMedCrossRef

16.

Fava A, Wung PK, Wigley FM, et al. Efficacy of Rho Kinase inhibitor fasudil in secondary Raynaud’s phenomenon. Arthritis Care Res. 2012;64:925–9.CrossRef

17.

Bredie SJ, Jong MC. No significant effect of Ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012;59:215–21.PubMedCrossRef

18.

Malenfant D, Summers K, Seney S, et al. Result of a pilot randomized placebo-controlled trial in primary and secondary Raynaud’s phenomenon with St. John’s Wort: detecting changes in angiogenic cytokines when RP improves. ISRN Rheumatol 2011; Article ID 580704, 6 pages. doi:10.5402/2011/580704.

19.

Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199–206.PubMed

20.

Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998; Issue 2: CD000953. doi: 10.1002/14651858

21.

Walker KM, Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol. 2011;38:1326–8.PubMedCrossRef

22.

Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial sympathectomy. J Hand Surg (American). 2009;34:1454–60.CrossRef

23.

Korn JH, Mayes M, Matucci Cerinic M, for the RAPIDS-1 Study Group, et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–93.PubMedCrossRef

24.

•• Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32–8. This double-blind, placebo-controlled trial confirmed the results of the previous RAPIDS-1 trial: bosentan was associated with a reduction in the number of new digital ulcers compared to placebo, but not with ulcer healing. All 188 patients with SSc, recruited from 41 centres, had at least one digital ulcer at the time of randomisation.PubMedCrossRef

25.

Arefiev K, Fiorentino DF, Chung L. Endothelin receptor antagonists for the treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol 2011; Article ID 201787, 7 pages, doi: 10.1155/2011/201787.

26.

Ivorra JA, Simeon CP, Sancho JJ, et al. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol. 2011;38:1631–5.CrossRef

27.

Nagai Y, Hasegawa M, Hattori T, et al. Bosentan for digital ulcers in patients with systemic sclerosis. J Dermatol. 2012;39:48–51.PubMedCrossRef

28.

Ichimura Y, Asano Y, Hatano M, et al. Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. Mod Rheumatol. 2011;21:548–52.PubMedCrossRef

29.

Taniguchi T, Asano Y, Hatano M, et al. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. Br J Dermatol. 2012;166:417–21.PubMedCrossRef

30.

Nguyen VA, Eisendle K, Gruber I, et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud’s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatol. 2010;49:583–7.CrossRef

31.

Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010;69:1475–8.PubMedCrossRef

32.

Della Rossa A, Doveri M, D’Ascanio A, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol. 2011;40:323–5.PubMedCrossRef

33.

Moinzadeh P, Hunzelmann N, Kreig T. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. J Am Acad Dermatol. 2011;65:e102–4.PubMedCrossRef

34.

Seibold JR, Wigley FM, Schiopu E, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study (abstract). Arthritis Rheum. 2010;63(Suppl):S968–9.

35.

Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Sem Arthritis Rheum. 2012;41:599–603.CrossRef

36.

Stone AV, Koman LA, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg (American Volume). 2012;37:795–802.CrossRef

37.

Yoshimasu T, Ikeda T, Uede K, et al. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. J Dermatol. 2012;39:536–40.PubMedCrossRef

38.

Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, et al. Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis. 1994;53:323–6.PubMedCrossRef

39.

Hasegawa M, Nagai Y, Tamura A, Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol. 2006;155:1159–64.PubMedCrossRef

40.

Zhang W, Xu JR, Lu Q, et al. High-resolution magnetic resonance angiography of digital arteries in SSc patients on a 3 Tesla: preliminary study. Rheumatol. 2011;50:1712–9.CrossRef

41.

Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902–12.PubMedCrossRef

42.

Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476–81.PubMedCrossRef

43.

Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis-spectrum disorders. Arthritis Rheum. 2010;62:2595–604.PubMedCrossRef

44.

Sebastiani M, Manfredi A, Colaci M, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum (Arthritis Care Res). 2009;61:688–94.CrossRef

45.

• Smith V, De Keyser F, Pizzorni C, et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis. 2011;70:180–3. The authors proposed a capillaroscopic index derived from capillary density as a predictor of digital trophic lesions. The importance of this study is that it emphasises how capillaroscopy may be a tool not only for predicting SSc in patients presenting with RP but also for predicting severity of vasculopathy.PubMedCrossRef

46.

Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801–8.PubMed

47.

Gabrielli A, Svegliati S, Moroncini G, et al. Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Semin Immunopathol. 2008;30:329–37.PubMedCrossRef

48.

Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980–5.PubMed

49.

Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166:231–3.PubMedCrossRef

50.

Schiopu E, Hsu VM, Impens AJ, et al. Randomised placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264–8.PubMedCrossRef

Title: Management of Raynaud’s Phenomenon and Digital Ischemia
Author: Ariane L. Herrick
Publication date: 01-01-2013
Publisher: Current Science Inc.
Published in: Current Rheumatology Reports / Issue 1/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-012-0303-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Morphogen Pathways in Systemic Sclerosis

The Immune Pathogenesis of Scleroderma: Context Is Everything

Dual-Energy Computed Tomography for Gout Diagnosis and Management

Personalized Treatment of Pain

Effect and Treatment of Chronic Pain in Inflammatory Arthritis

Epidemiology and Risk Factors for Pulmonary Hypertension in Systemic Sclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials